Pharma: Increase Income - Focus Resources on Core Domains, Steady Sales Growth and Further Low-Cost Operations

	TOP

	Financial Results - For the FYE March 2017 -

	Contents

	1. Overview for the FYE March 2017

	2. Outlook for the FYE March 2018 Food: Increase Income - Grow Sales of Core Products and Reduce Cost Food: Expand Domestic Share of Core Products - Accelerate Selection and Concentration Food: Continue Structural Reforms Food: Overseas Business - Stabilize Profitability and Challenge for Further Growth Pharma: Increase Income - Focus Resources on Core Domains, Steady Sales Growth and Further Low-Cost Operations Pharma: Steady sales growth in Japan and overseas Pharma: Further Expand Generic Drug Business - Add New Business Model Plan - FYE March 2018 Use of Cash Flows Summary - Progress in STEP UP 17 Strategy

	3. The Meiji Group 2026 Vision (outline)

	Appendix

	Back cover

Pharmaceuticals segment
Operating Income: JPY 11.0 billion, YoY increase of JPY 5.2 billion

• Grow income by increasing in sales volume

Sycrest and Bilanoa: newly launched products in FYE March 2017

Reflex

Generics

• Streamlining the number of generic products

• Company-wide cost control by improving efficiency